Genetic Susceptibility to Tardive Dyskinesia and Cognitive Impairments in Chinese Han Schizophrenia: Role of Oxidative Stress-Related and Adenosine Receptor Genes
Objective: Tardive dyskinesia (TD) is a severe rhythmic movement disorder caused by long-term antipsychotic medication in chronic patients with schizophrenia (SCZ). We aimed to investigate the association between polymorphisms in oxidative stress-related genes (GSTM1, SOD2, NOS1, and NOS3) and adeno...
Saved in:
Published in | Neuropsychiatric disease and treatment Vol. 19; pp. 2499 - 2509 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Dove Medical Press Limited
30.11.2023
Dove Medical Press |
Subjects | |
Online Access | Get full text |
ISSN | 1178-2021 1176-6328 1178-2021 |
DOI | 10.2147/NDT.S427557 |
Cover
Abstract | Objective: Tardive dyskinesia (TD) is a severe rhythmic movement disorder caused by long-term antipsychotic medication in chronic patients with schizophrenia (SCZ). We aimed to investigate the association between polymorphisms in oxidative stress-related genes (GSTM1, SOD2, NOS1, and NOS3) and adenosine receptor gene (ADORA2A), as well as their interactions, with the occurrence and severity of TD, and cognitive impairments in a Chinese Han population of SCZ patients. Methods: Two hundred and sixteen SCZ patients were recruited and divided into TD group (n=157) and non-TD group (n=59). DNA extraction was performed by a high-salt method, followed by SNP genotyping using matrix-assisted laser desorption ionization time-of -flight mass spectrometry (MALDI-TOF-MS). The severity of TD, psychopathology and cognitive functioning were assessed using the Abnormal Involuntary Movement Scale (AIMS), the Positive and Negative Syndrome Scale (PANSS) and the Repeated Battery for Assessment of Neuropsychological Status (RBANS), respectively. Results: The combination of GSTM1 -rs738491, NOS1-rs738409 and ADORA2A-rs229883 was identified as the best three-point model to predict TD occurrence (p=0.01). Additionally, GSTM-rs738491 CC or NOS3-rs1800779 AG genotypes may be protective factors for psychiatric symptoms in TD patients. TD patients carrying the NOS1 -rs738409 AG or ADORA2A-rs229883 TT genotypes exhibited poorer cognitive performance. Conclusion: Our findings suggest that the interaction of oxidative stress-related genes and adenosine receptor gene may play a role in the susceptibility and severity of TD in Chinese Han SCZ patient. Furthermore, these genes may also affect the psychiatric symptoms and cognitive function of TD patients. Keywords: tardive dyskinesia, schizophrenia, oxidative stress, adenosine receptor, polymorphisms, cognitive impairments |
---|---|
AbstractList | Objective: Tardive dyskinesia (TD) is a severe rhythmic movement disorder caused by long-term antipsychotic medication in chronic patients with schizophrenia (SCZ). We aimed to investigate the association between polymorphisms in oxidative stress-related genes (GSTM1, SOD2, NOS1, and NOS3) and adenosine receptor gene (ADORA2A), as well as their interactions, with the occurrence and severity of TD, and cognitive impairments in a Chinese Han population of SCZ patients. Methods: Two hundred and sixteen SCZ patients were recruited and divided into TD group (n=157) and non-TD group (n=59). DNA extraction was performed by a high-salt method, followed by SNP genotyping using matrix-assisted laser desorption ionization time-of -flight mass spectrometry (MALDI-TOF-MS). The severity of TD, psychopathology and cognitive functioning were assessed using the Abnormal Involuntary Movement Scale (AIMS), the Positive and Negative Syndrome Scale (PANSS) and the Repeated Battery for Assessment of Neuropsychological Status (RBANS), respectively. Results: The combination of GSTM1 -rs738491, NOS1-rs738409 and ADORA2A-rs229883 was identified as the best three-point model to predict TD occurrence (p=0.01). Additionally, GSTM-rs738491 CC or NOS3-rs1800779 AG genotypes may be protective factors for psychiatric symptoms in TD patients. TD patients carrying the NOS1 -rs738409 AG or ADORA2A-rs229883 TT genotypes exhibited poorer cognitive performance. Conclusion: Our findings suggest that the interaction of oxidative stress-related genes and adenosine receptor gene may play a role in the susceptibility and severity of TD in Chinese Han SCZ patient. Furthermore, these genes may also affect the psychiatric symptoms and cognitive function of TD patients. Keywords: tardive dyskinesia, schizophrenia, oxidative stress, adenosine receptor, polymorphisms, cognitive impairments Tardive dyskinesia (TD) is a severe rhythmic movement disorder caused by long-term antipsychotic medication in chronic patients with schizophrenia (SCZ). We aimed to investigate the association between polymorphisms in oxidative stress-related genes (GSTM1, SOD2, NOS1, and NOS3) and adenosine receptor gene (ADORA2A), as well as their interactions, with the occurrence and severity of TD, and cognitive impairments in a Chinese Han population of SCZ patients.ObjectiveTardive dyskinesia (TD) is a severe rhythmic movement disorder caused by long-term antipsychotic medication in chronic patients with schizophrenia (SCZ). We aimed to investigate the association between polymorphisms in oxidative stress-related genes (GSTM1, SOD2, NOS1, and NOS3) and adenosine receptor gene (ADORA2A), as well as their interactions, with the occurrence and severity of TD, and cognitive impairments in a Chinese Han population of SCZ patients.Two hundred and sixteen SCZ patients were recruited and divided into TD group (n=157) and non-TD group (n=59). DNA extraction was performed by a high-salt method, followed by SNP genotyping using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS). The severity of TD, psychopathology and cognitive functioning were assessed using the Abnormal Involuntary Movement Scale (AIMS), the Positive and Negative Syndrome Scale (PANSS) and the Repeated Battery for Assessment of Neuropsychological Status (RBANS), respectively.MethodsTwo hundred and sixteen SCZ patients were recruited and divided into TD group (n=157) and non-TD group (n=59). DNA extraction was performed by a high-salt method, followed by SNP genotyping using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS). The severity of TD, psychopathology and cognitive functioning were assessed using the Abnormal Involuntary Movement Scale (AIMS), the Positive and Negative Syndrome Scale (PANSS) and the Repeated Battery for Assessment of Neuropsychological Status (RBANS), respectively.The combination of GSTM1-rs738491, NOS1-rs738409 and ADORA2A-rs229883 was identified as the best three-point model to predict TD occurrence (p=0.01). Additionally, GSTM-rs738491 CC or NOS3-rs1800779 AG genotypes may be protective factors for psychiatric symptoms in TD patients. TD patients carrying the NOS1-rs738409 AG or ADORA2A-rs229883 TT genotypes exhibited poorer cognitive performance.ResultsThe combination of GSTM1-rs738491, NOS1-rs738409 and ADORA2A-rs229883 was identified as the best three-point model to predict TD occurrence (p=0.01). Additionally, GSTM-rs738491 CC or NOS3-rs1800779 AG genotypes may be protective factors for psychiatric symptoms in TD patients. TD patients carrying the NOS1-rs738409 AG or ADORA2A-rs229883 TT genotypes exhibited poorer cognitive performance.Our findings suggest that the interaction of oxidative stress-related genes and adenosine receptor gene may play a role in the susceptibility and severity of TD in Chinese Han SCZ patient. Furthermore, these genes may also affect the psychiatric symptoms and cognitive function of TD patients.ConclusionOur findings suggest that the interaction of oxidative stress-related genes and adenosine receptor gene may play a role in the susceptibility and severity of TD in Chinese Han SCZ patient. Furthermore, these genes may also affect the psychiatric symptoms and cognitive function of TD patients. Qiaona Jiang,1,* Xiaofei Zhang,1,* Xiaohui Lu,2 Yanzhe Li,3 Chenghao Lu,1 Jinghui Chi,1 Yanyan Ma,1 Xiaomei Shi,1 Lili Wang,1 Shen Li3 1Department of Psychiatry, Tianjin Anding Hospital, Mental Health Center of Tianjin Medical University, Tianjin, People’s Republic of China; 2Department of Psychiatry, Qingdao Mental Health Center, Qingdao, People’s Republic of China; 3Institute of Mental Health, Tianjin Anding Hospital, Mental Health Center of Tianjin Medical University, Tianjin, People’s Republic of China*These authors contributed equally to this workCorrespondence: Lili Wang, Department of Psychiatry, Tianjin Anding Hospital, Mental Health Center of Tianjin Medical University, No. 13, Liulin Road, Hexi District, Tianjin, 300222, People’s Republic of China, Tel +00-86-022-88188796, Email tjadyywll@163.com Shen Li, Institute of Mental Health, Tianjin Anding Hospital, Mental Health Center of Tianjin Medical University, No. 13, Liulin Road, Hexi District, Tianjin, 300222, People’s Republic of China, Tel +00-86-022-88188875, Email lishen@tmu.edu.cnObjective: Tardive dyskinesia (TD) is a severe rhythmic movement disorder caused by long-term antipsychotic medication in chronic patients with schizophrenia (SCZ). We aimed to investigate the association between polymorphisms in oxidative stress-related genes (GSTM1, SOD2, NOS1, and NOS3) and adenosine receptor gene (ADORA2A), as well as their interactions, with the occurrence and severity of TD, and cognitive impairments in a Chinese Han population of SCZ patients.Methods: Two hundred and sixteen SCZ patients were recruited and divided into TD group (n=157) and non-TD group (n=59). DNA extraction was performed by a high-salt method, followed by SNP genotyping using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS). The severity of TD, psychopathology and cognitive functioning were assessed using the Abnormal Involuntary Movement Scale (AIMS), the Positive and Negative Syndrome Scale (PANSS) and the Repeated Battery for Assessment of Neuropsychological Status (RBANS), respectively.Results: The combination of GSTM1-rs738491, NOS1-rs738409 and ADORA2A-rs229883 was identified as the best three-point model to predict TD occurrence (p=0.01). Additionally, GSTM-rs738491 CC or NOS3-rs1800779 AG genotypes may be protective factors for psychiatric symptoms in TD patients. TD patients carrying the NOS1-rs738409 AG or ADORA2A-rs229883 TT genotypes exhibited poorer cognitive performance.Conclusion: Our findings suggest that the interaction of oxidative stress-related genes and adenosine receptor gene may play a role in the susceptibility and severity of TD in Chinese Han SCZ patient. Furthermore, these genes may also affect the psychiatric symptoms and cognitive function of TD patients.Keywords: tardive dyskinesia, schizophrenia, oxidative stress, adenosine receptor, polymorphisms, cognitive impairments |
Audience | Academic |
Author | Zhang, Xiaofei Ma, Yanyan Wang, Lili Lu, Chenghao Li, Yanzhe Li, Shen Lu, Xiaohui Chi, Jinghui Jiang, Qiaona Shi, Xiaomei |
Author_xml | – sequence: 1 givenname: Qiaona surname: Jiang fullname: Jiang, Qiaona – sequence: 2 givenname: Xiaofei surname: Zhang fullname: Zhang, Xiaofei – sequence: 3 givenname: Xiaohui surname: Lu fullname: Lu, Xiaohui – sequence: 4 givenname: Yanzhe surname: Li fullname: Li, Yanzhe – sequence: 5 givenname: Chenghao surname: Lu fullname: Lu, Chenghao – sequence: 6 givenname: Jinghui surname: Chi fullname: Chi, Jinghui – sequence: 7 givenname: Yanyan surname: Ma fullname: Ma, Yanyan – sequence: 8 givenname: Xiaomei surname: Shi fullname: Shi, Xiaomei – sequence: 9 givenname: Lili surname: Wang fullname: Wang, Lili – sequence: 10 givenname: Shen surname: Li fullname: Li, Shen |
BookMark | eNptkm9rUzEUhy8ywW36yi8QEEQYrUnun6S-G51uheGgra_Ducm5beZtUpNUrB_HT2puO2STkRcJJ895-CWcs-LEeYdF8ZbRMWeV-Pj1ajleVFzUtXhRnDIm5IhTzk4enV8VZzHeU1qKiZSnxZ9rdJisJotd1LhNtrW9TXuSPFlCMPYnkqt9_G4dRgsEnCFTv3I2DRezzRZs2KBLkVhHpuuBQnIDjiz02v7223VAZ-ETmfseie_I3S9r4NC7SAFjHM2xh4TmIL406HzMDjLHIYoPZAgXXxcvO-gjvnnYz4tvXz4vpzej27vr2fTydqSrRqRRU2pBa2OEBMkkVhpp14qOadPkQ1tpyktZtqaivBI166ipedW0lDFmOJRteV7Mjl7j4V5tg91A2CsPVh0KPqwUhPxVPaqKNaJlNQdGs1ijBFY3E5ndwnCBg-vD0bUN_scOY1Ibm_-378Gh30XF5aTOaXlVZfTdEV1BNlvX-RRAD7i6FELmeLJhmRo_Q-VlcGN1noLO5vqThvePGtYIfVpH3--S9S4-BS-OoA4-xoDdv6czqoapUnmq1MNUZZr9R2ubYJDmPLZ_tucvXEDRPA |
CitedBy_id | crossref_primary_10_1093_schbul_sbaf006 |
Cites_doi | 10.1016/j.pnpbp.2006.12.019 10.1089/ars.2010.3603 10.3389/fphar.2021.834129 10.1038/364626a0 10.1038/sj.cr.7290272 10.1001/archpsyc.1973.01750340009001 10.1093/schbul/13.2.261 10.1146/annurev.pa.30.040190.002535 10.1176/jnp.7.2.223 10.1016/j.neuropharm.2011.01.048 10.1023/A:1005427323835 10.1097/01.fpc.0000184958.05775.66 10.1016/j.bbi.2022.01.006 10.1016/S0278-5846(00)00181-0 10.1034/j.1601-0825.2003.02866.x 10.1111/j.1748-1716.1990.tb08923.x 10.1007/s40120-018-0105-0 10.1097/MD.0000000000001507 10.1089/omi.2016.0003 10.4088/JCP.v68n0513 10.1016/j.schres.2006.12.019 10.1016/j.bbamem.2010.12.001 10.2147/NDT.S205014 10.1093/schbul/sbp006 10.1111/j.1749-6632.1989.tb14918.x 10.1076/jcen.20.3.310.823 10.1139/H07-081 10.1093/nar/19.19.5444 10.2165/00023210-200317010-00004 10.1042/bj3240025 10.1097/00008877-200105000-00006 10.1017/S1461145707008401 10.1093/schbul/sbv167 10.1016/j.jpsychires.2022.04.029 10.1155/2022/5748924 10.1007/s11920-007-0041-7 10.1155/2021/8881770 10.1177/070674370505000907 10.1007/s00702-004-0118-y 10.1001/archpsyc.1982.04290040080012 10.1080/j.1440-1614.2000.00737.x 10.1016/j.pnpbp.2012.10.018 10.1016/0006-3223(90)90461-A 10.1086/518312 10.1038/s41398-021-01471-y 10.1016/0006-3223(90)90490-S 10.2147/NDT.S235043 10.1006/abbi.2001.2630 10.1016/j.ajp.2021.102877 10.4088/JCP.16r10832 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2023 Dove Medical Press Limited 2023 Jiang et al. |
Copyright_xml | – notice: COPYRIGHT 2023 Dove Medical Press Limited – notice: 2023 Jiang et al. |
DBID | AAYXX CITATION 7X8 DOA |
DOI | 10.2147/NDT.S427557 |
DatabaseName | CrossRef MEDLINE - Academic DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1178-2021 |
EndPage | 2509 |
ExternalDocumentID | oai_doaj_org_article_4167b152a10b4cce8a15698d407d27eb A778111861 10_2147_NDT_S427557 |
GeographicLocations | China |
GeographicLocations_xml | – name: China |
GroupedDBID | --- 0YH 123 29N 2WC 53G 5VS 7RV 7X7 8AO 8FE 8FH 8FI 8FJ 8G5 AAFWJ AAYXX ABIVO ABUWG ACGFO ADBBV ADRAZ AENEX AFKRA AFPKN AIAGR ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BKEYQ BPHCQ BVXVI CCPQU CITATION CS3 DIK DWQXO E3Z EBD EBS EJD F5P FYUFA GNUQQ GROUPED_DOAJ GUQSH GX1 HCIFZ HMCUK HYE IAO IHR IHW IPNFZ IPY ITC KQ8 LK8 M2M M2O M48 M7P NAPCQ O5R O5S OK1 P2P P6G PHGZM PHGZT PIMPY PQQKQ PROAC PSYQQ RIG RNS RPM TDBHL TR2 UKHRP VDV PMFND 7X8 PPXIY PQGLB PUEGO |
ID | FETCH-LOGICAL-c467t-63c705dd78a818e4ce0fb7f1cd60fbb4c02383bd4024751f0d5246b0111d2a3b3 |
IEDL.DBID | M48 |
ISSN | 1178-2021 1176-6328 |
IngestDate | Wed Aug 27 01:28:26 EDT 2025 Fri Sep 05 09:24:31 EDT 2025 Tue Jun 17 22:27:31 EDT 2025 Tue Jun 10 21:15:57 EDT 2025 Thu May 22 21:06:09 EDT 2025 Thu Apr 24 23:03:47 EDT 2025 Tue Jul 01 04:35:29 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Language | English |
License | https://creativecommons.org/licenses/by-nc/3.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c467t-63c705dd78a818e4ce0fb7f1cd60fbb4c02383bd4024751f0d5246b0111d2a3b3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://doaj.org/article/4167b152a10b4cce8a15698d407d27eb |
PQID | 2895705244 |
PQPubID | 23479 |
PageCount | 11 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_4167b152a10b4cce8a15698d407d27eb proquest_miscellaneous_2895705244 gale_infotracmisc_A778111861 gale_infotracacademiconefile_A778111861 gale_healthsolutions_A778111861 crossref_primary_10_2147_NDT_S427557 crossref_citationtrail_10_2147_NDT_S427557 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 20231130 |
PublicationDateYYYYMMDD | 2023-11-30 |
PublicationDate_xml | – month: 11 year: 2023 text: 20231130 day: 30 |
PublicationDecade | 2020 |
PublicationTitle | Neuropsychiatric disease and treatment |
PublicationYear | 2023 |
Publisher | Dove Medical Press Limited Dove Medical Press |
Publisher_xml | – name: Dove Medical Press Limited – name: Dove Medical Press |
References | Hitzeroth (ref41) 2007; 31 Cho (ref17) 2013; 46 Leucht (ref31) 2016; 42 Turcin (ref30) 2016; 20 Boison (ref28) 2012; 62 Huang (ref40) 2022; 2022 Tsermpini (ref5) 2021; 12 Howes (ref11) 2009; 35 Yao (ref50) 2011; 15 Gomes (ref52) 2011; 1808 Carbon (ref2) 2017; 78 Miao (ref29) 2019; 15 Radak (ref19) 2007; 32 Gronau (ref43) 2003; 9 Ignarro (ref46) 1990; 30 Liang (ref4) 2022; 151 Cadet (ref13) 1989; 570 Hensley (ref12) 2002; 397 Ng (ref14) 2008; 11 Wang (ref25) 2015; 94 Kruk (ref9) 1995; 7 Ermakov (ref53) 2021; 2021 Margolese (ref6) 2005; 50 Lipton (ref22) 1993; 364 Lahiri (ref36) 1991; 19 Baez (ref20) 1997; 324 McNeill (ref45) 2022; 101 Thelma (ref18) 2007; 92 Lohr (ref15) 1990; 28 Cadet (ref16) 1990; 28 Shi (ref37) 2005; 15 Zhang (ref44) 2007; 68 Toda (ref51) 2007; 9 Wang (ref27) 2004; 111 Sachdev (ref10) 2000; 34 Freedman (ref1) 1973; 28 Lim (ref39) 2021; 11 Liou (ref26) 2006; 16 Lohr (ref8) 2003; 17 Randolph (ref34) 1998; 20 Furchgott (ref47) 1990; 139 Kay (ref33) 1987; 13 Robinson (ref21) 1998; 21 Lou (ref38) 2007; 80 Zhang (ref35) 2009; 28 Mahadik (ref49) 2001; 25 Ward (ref7) 2018; 7 Zhang (ref42) 2020; 99 Naidu (ref48) 2001; 12 Uludag (ref3) 2021; 66 Uludag (ref24) 2022; 2022 Johnson (ref32) 1982; 39 Yan (ref23) 2020; 16 |
References_xml | – volume: 31 start-page: 664 year: 2007 ident: ref41 publication-title: Prog Neuropsychopharmacol Biol Psychiatry doi: 10.1016/j.pnpbp.2006.12.019 – volume: 15 start-page: 2011 year: 2011 ident: ref50 publication-title: Antioxid Redox Signal doi: 10.1089/ars.2010.3603 – volume: 12 start-page: 834129 year: 2021 ident: ref5 publication-title: Front Pharmacol doi: 10.3389/fphar.2021.834129 – volume: 364 start-page: 626 year: 1993 ident: ref22 publication-title: Nature doi: 10.1038/364626a0 – volume: 15 start-page: 97 year: 2005 ident: ref37 publication-title: Cell Res doi: 10.1038/sj.cr.7290272 – volume: 28 start-page: 463 year: 1973 ident: ref1 publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.1973.01750340009001 – volume: 13 start-page: 261 year: 1987 ident: ref33 publication-title: Schizophrenia Bulletin doi: 10.1093/schbul/13.2.261 – volume: 30 start-page: 535 year: 1990 ident: ref46 publication-title: Annu Rev Pharmacol Toxicol doi: 10.1146/annurev.pa.30.040190.002535 – volume: 7 start-page: 223 year: 1995 ident: ref9 publication-title: J Neuropsychiatry Clin Neurosci doi: 10.1176/jnp.7.2.223 – volume: 62 start-page: 1527 year: 2012 ident: ref28 publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2011.01.048 – volume: 28 start-page: 865 year: 2009 ident: ref35 publication-title: J Chin Ment Health – volume: 21 start-page: 598 year: 1998 ident: ref21 publication-title: J Inherit Metab Dis doi: 10.1023/A:1005427323835 – volume: 16 start-page: 151 year: 2006 ident: ref26 publication-title: Pharmacogenet Genomics doi: 10.1097/01.fpc.0000184958.05775.66 – volume: 101 start-page: 275 year: 2022 ident: ref45 publication-title: Brain Behav Immun doi: 10.1016/j.bbi.2022.01.006 – volume: 25 start-page: 463 year: 2001 ident: ref49 publication-title: Prog Neuropsychopharmacol Biol Psychiatry doi: 10.1016/S0278-5846(00)00181-0 – volume: 9 start-page: 62 year: 2003 ident: ref43 publication-title: Oral Dis doi: 10.1034/j.1601-0825.2003.02866.x – volume: 139 start-page: 257 year: 1990 ident: ref47 publication-title: Acta Physiol Scand doi: 10.1111/j.1748-1716.1990.tb08923.x – volume: 7 start-page: 233 year: 2018 ident: ref7 publication-title: Neurol Ther doi: 10.1007/s40120-018-0105-0 – volume: 94 start-page: e1507 year: 2015 ident: ref25 publication-title: Medicine (Baltimore) doi: 10.1097/MD.0000000000001507 – volume: 20 start-page: 283 year: 2016 ident: ref30 publication-title: OMICS doi: 10.1089/omi.2016.0003 – volume: 68 start-page: 754 year: 2007 ident: ref44 publication-title: J Clin Psychiatry doi: 10.4088/JCP.v68n0513 – volume: 92 start-page: 278 year: 2007 ident: ref18 publication-title: Schizophr Res doi: 10.1016/j.schres.2006.12.019 – volume: 1808 start-page: 1380 year: 2011 ident: ref52 publication-title: Biochimica et Biophysica Acta doi: 10.1016/j.bbamem.2010.12.001 – volume: 15 start-page: 2451 year: 2019 ident: ref29 publication-title: Neuropsychiatr Dis Treat doi: 10.2147/NDT.S205014 – volume: 35 start-page: 549 year: 2009 ident: ref11 publication-title: Schizophr Bull doi: 10.1093/schbul/sbp006 – volume: 570 start-page: 176 year: 1989 ident: ref13 publication-title: Ann N Y Acad Sci doi: 10.1111/j.1749-6632.1989.tb14918.x – volume: 20 start-page: 310 year: 1998 ident: ref34 publication-title: J Clin Exp Neuropsychol doi: 10.1076/jcen.20.3.310.823 – volume: 32 start-page: 942 year: 2007 ident: ref19 publication-title: Appl Physiol Nutr Metab doi: 10.1139/H07-081 – volume: 19 start-page: 5444 year: 1991 ident: ref36 publication-title: Nucleic Acids Res doi: 10.1093/nar/19.19.5444 – volume: 17 start-page: 47 year: 2003 ident: ref8 publication-title: CNS Drugs doi: 10.2165/00023210-200317010-00004 – volume: 324 start-page: 25 year: 1997 ident: ref20 publication-title: Biochem J doi: 10.1042/bj3240025 – volume: 12 start-page: 209 year: 2001 ident: ref48 publication-title: Behav Pharmacol doi: 10.1097/00008877-200105000-00006 – volume: 11 start-page: 851 year: 2008 ident: ref14 publication-title: Int J Neuropsychopharmacol doi: 10.1017/S1461145707008401 – volume: 42 start-page: S90 year: 2016 ident: ref31 publication-title: Schizophr Bull doi: 10.1093/schbul/sbv167 – volume: 151 start-page: 181 year: 2022 ident: ref4 publication-title: J Psychiatr Res doi: 10.1016/j.jpsychires.2022.04.029 – volume: 2022 start-page: 5748924 year: 2022 ident: ref24 publication-title: Oxid Med Cell Longev doi: 10.1155/2022/5748924 – volume: 9 start-page: 329 year: 2007 ident: ref51 publication-title: Curr Psychiatry Rep doi: 10.1007/s11920-007-0041-7 – volume: 2021 start-page: 8881770 year: 2021 ident: ref53 publication-title: Oxid Med Cell Longev doi: 10.1155/2021/8881770 – volume: 50 start-page: 541 year: 2005 ident: ref6 publication-title: Can J Psychiatry doi: 10.1177/070674370505000907 – volume: 111 start-page: 623 year: 2004 ident: ref27 publication-title: Journal of Neural Transmission doi: 10.1007/s00702-004-0118-y – volume: 39 start-page: 486 year: 1982 ident: ref32 publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.1982.04290040080012 – volume: 34 start-page: 355 year: 2000 ident: ref10 publication-title: Aust N Z J Psychiatry doi: 10.1080/j.1440-1614.2000.00737.x – volume: 2022 start-page: 1075440 year: 2022 ident: ref40 publication-title: Oxid Med Cell Longev – volume: 46 start-page: 207 year: 2013 ident: ref17 publication-title: Prog Neuropsychopharmacol Biol Psychiatry doi: 10.1016/j.pnpbp.2012.10.018 – volume: 28 start-page: 738 year: 1990 ident: ref16 publication-title: Biol Psychiatry doi: 10.1016/0006-3223(90)90461-A – volume: 80 start-page: 1125 year: 2007 ident: ref38 publication-title: Am J Hum Genet doi: 10.1086/518312 – volume: 11 start-page: 351 year: 2021 ident: ref39 publication-title: Transl Psychiatry doi: 10.1038/s41398-021-01471-y – volume: 99 start-page: e54 year: 2020 ident: ref42 publication-title: Medicine – volume: 28 start-page: 535 year: 1990 ident: ref15 publication-title: Biol Psychiatry doi: 10.1016/0006-3223(90)90490-S – volume: 16 start-page: 479 year: 2020 ident: ref23 publication-title: Neuropsychiatr Dis Treat doi: 10.2147/NDT.S235043 – volume: 397 start-page: 377 year: 2002 ident: ref12 publication-title: Arch Biochem Biophys doi: 10.1006/abbi.2001.2630 – volume: 66 start-page: 102877 year: 2021 ident: ref3 publication-title: Asian J Psychiatr doi: 10.1016/j.ajp.2021.102877 – volume: 78 start-page: e264 year: 2017 ident: ref2 publication-title: J Clin Psychiatry doi: 10.4088/JCP.16r10832 |
SSID | ssj0037988 |
Score | 2.3379261 |
Snippet | Objective: Tardive dyskinesia (TD) is a severe rhythmic movement disorder caused by long-term antipsychotic medication in chronic patients with schizophrenia... Tardive dyskinesia (TD) is a severe rhythmic movement disorder caused by long-term antipsychotic medication in chronic patients with schizophrenia (SCZ). We... Qiaona Jiang,1,* Xiaofei Zhang,1,* Xiaohui Lu,2 Yanzhe Li,3 Chenghao Lu,1 Jinghui Chi,1 Yanyan Ma,1 Xiaomei Shi,1 Lili Wang,1 Shen Li3 1Department of... |
SourceID | doaj proquest gale crossref |
SourceType | Open Website Aggregation Database Enrichment Source Index Database |
StartPage | 2499 |
SubjectTerms | adenosine receptor Cell receptors Cognition disorders cognitive impairments Development and progression Drug therapy Genetic aspects Health aspects Oxidative stress Physiological aspects polymorphisms Risk factors Schizophrenia Single nucleotide polymorphisms Tardive dyskinesia |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3fa9RAEF6kD8UXqVXp1VpHKAhCbLLZZHN9O1vLKbSCd4W-LfsTjpZELndi_x3_Umc2ueMOLL74FnaHsNlvZ2eGzHzD2EkQFc-tLJOAxi0RkueJiZVcoSpECEOfx16HV9fl-EZ8vS1uN1p9UU5YRw_cbdwpOgzSoJHRWWqEtb7SGHEMK4eBiOPSG7p902G6Cqa6OzgnFq6uGo_68JxeX0w_TgSXBVmhDfsTafofu4yjhbncY8961xBG3ZKesye-3me7V_3P7xfsN1FE4xxMlm1MRol5rQ-waGBKOP_0cPHQ3lEe-0yDrh2cr3KD4Atq_Wwey9lgVgN1zfath7GuYbKZdncG35t7D02Ab79mLpKCwySWkyQxbc67-OKRI45xfAeg24lLaeZAi2tfspvLz9PzcdK3WEgs3pCLpESc0sI5WWm03F5YnwYjQ2ZdiQ-44WTSc4O7zYUsspC6govSUIN6x3Vu8ldsp25qf8DABIljwum8cEKLUpdZFrg3QgfUemMG7MNq45Xt-cepDca9wjiEUFKIkupRGrCTtfCPjnbj72KfCMG1CHFlxwE8Qao_QepfJ2jA3hL-qis8XWu8Gkmqws2qMhuw91GCdB6XbHVfuoAfTuxZW5JHW5Koq3Zr-t3qjCmaogS32jfLVmHcWyAS6Gwd_o9ves2ecoSu46g8YjuL-dK_Qe9pYY6jovwBUOQYZQ priority: 102 providerName: Directory of Open Access Journals |
Title | Genetic Susceptibility to Tardive Dyskinesia and Cognitive Impairments in Chinese Han Schizophrenia: Role of Oxidative Stress-Related and Adenosine Receptor Genes |
URI | https://www.proquest.com/docview/2895705244 https://doaj.org/article/4167b152a10b4cce8a15698d407d27eb |
Volume | 19 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3ri9NAEF_uAeIX8YnVs45wIAg5m2STzQkivRdVaJVrC_227GZ3pVgSTVq5_jv-pc5s0mLlBL-F7CTsZmbnkZ35DWPHjmdRnIs0cGjcAi6iONC-kstlCXfu1Ma-1-FwlA6m_NMsme2xTTPO9gPWt4Z21E9qWi1Obn6sP-CGf09pzCEXb0cXk5Mxj0SSiH12iCYppShsyLfHCTGBcjVdVkgsorAp1Pv74R3T5BH8_6WnvfG5us_utV4j9Bs2P2B7tnjI7gzbc_FH7BehR-MYjFe1z1PxKa9rWJYwIRH4aeFiXX-jFPe5AlUYON-kDcFHVAjzyle6wbwAaqhtawsDVcD4z4y8d3BdLiyUDj7fzI3HC4exrzQJfEadNf7FfUPw4_gOQI8Up1JWQJOrH7Pp1eXkfBC03ReCHJXnMkiRhb3EGJEpNOqW57bntHBhblK80Dwnax9rgwEoF0noeiaJeKqpd72JVKzjJ-ygKAv7lIF2Au9xo-LEcMVTlYahi6zmyqFC0LrD3mw-vMxbaHLqkLGQGKIQlyRySbZc6rDjLfH3BpHjdrIz4uCWhGC0_Y2y-irbXSlJVDR6MCrs4YJymykMZ08zXJMwkbA4sZfEf9nUpG6VgewLKtANszTssNeeggQUp5yrtqoBF07AWjuURzuUuI3zneFXGxmTNES5b4UtV7XEkDhBTqAf9uz_lv6c3UUhjxuAyiN2sKxW9gW6TkvdZftiJrrs8Oxy9OW6639AdP1W-Q0HbhnJ |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Genetic+Susceptibility+to+Tardive+Dyskinesia+and+Cognitive+Impairments+in+Chinese+Han+Schizophrenia%3A+Role+of+Oxidative+Stress-Related+and+Adenosine+Receptor+Genes&rft.jtitle=Neuropsychiatric+disease+and+treatment&rft.au=Jiang%2C+Qiaona&rft.au=Zhang%2C+Xiaofei&rft.au=Lu%2C+Xiaohui&rft.au=Li%2C+Yanzhe&rft.date=2023-11-30&rft.issn=1178-2021&rft.eissn=1178-2021&rft.volume=19&rft.spage=2499&rft.epage=2509&rft_id=info:doi/10.2147%2FNDT.S427557&rft.externalDBID=n%2Fa&rft.externalDocID=10_2147_NDT_S427557 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1178-2021&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1178-2021&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1178-2021&client=summon |